Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This is an open label, non-randomized, single arm phase II study. The primary objective of
this study is to investigate the efficacy of combination of sorafenib and VELCADE®
(bortezomib). The primary efficacy endpoint is Progression-Free Survival (PFS). The secondary
objectives of this study are to:
Assess the response rate of this combination in this patient population and Assess the
toxicity of this combination in this patient population